Evidence map›Paper›PMID 29402726›Full record

ArticleEBioMedicine2018

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.

Jinghan Wang, Fenglin Li, Zhixin Ma, Mengxia Yu, Qi Guo, Jiansong Huang, Wenjuan Yu, Yungui Wang, Jie Jin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.Journal of experimental & clinical cancer research : CR · 2022
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Ten-eleven translocase: key regulator of the methylation landscape in cancer.Journal of cancer research and clinical oncology · 2021
    Review
  16. Review
  17. Article
  18. Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease).Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jinghan WangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, PR China; Institute of Hematology, Zhejiang University, Hangzhou, PR China; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, Hangzhou, PR China.
Fenglin LiInstitute of Hematology, Zhejiang University, Hangzhou, PR China.
Zhixin MaInstitute of Hematology, Zhejiang University, Hangzhou, PR China.
Mengxia YuInstitute of Hematology, Zhejiang University, Hangzhou, PR China.
Qi GuoDepartment of Nephrology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Jiansong HuangInstitute of Hematology, Zhejiang University, Hangzhou, PR China; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, Hangzhou, PR China.
Wenjuan YuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, PR China; Institute of Hematology, Zhejiang University, Hangzhou, PR China; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, Hangzhou, PR China.
Yungui WangInstitute of Hematology, Zhejiang University, Hangzhou, PR China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, PR China; Institute of Hematology, Zhejiang University, Hangzhou, PR China; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, Hangzhou, PR China. Electronic address: jiej0503@zju.edu.cn.
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ten-Eleven-Translocation 1 (TET1) plays a role in the DNA methylation process and gene activation. Recent reports suggest TET1 acts as an oncogene in leukemia development. However, the clinical relevance and biological insight of TET1 expression in cytogenetically normal acute myeloid leukemia (CN-AML) is unknown. In this study, quantification of TET1 transcript by real-time quantitative PCR in bone marrow blasts was performed in 360 CN-AML patients. As a result, high TET1 expression was more common in M0/M1 morphology and genes of NPM1 mutations, and underrepresented in CEBPA double allele mutations in our AML patients. In addition, we found overexpression of TET1 was associated with an inferior overall survival and event free survival in the two independent cohorts. Notably, mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers. In conclusion, the TET1 gene expression might serve as a reliable predictor for patients survival in AML.

Indexed as

Cytogenetic AnalysisCohort StudiesFemaleGene Expression ProfilingGene Expression Regulation, LeukemicHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMicroRNAsMiddle AgedMixed Function OxygenasesMultivariate AnalysisNucleophosminPrognosisProto-Oncogene ProteinsMicroRNAsMixed Function OxygenasesNPM1 protein, humanNucleophosminProto-Oncogene ProteinsRNA, MessengerTET1 protein, humanAcute myeloid leukemiaPrognosisSurvivalTET1

Identifiers

PMID29402726
PMCPMC5835576
OpenAlexW2791744951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.